TaiAn Technologies Corporation
TaiAn Technologies Corporation, founded in 2002 and based in Taipei, is a technology advisory firm focused on commercializing intellectual properties in the life sciences sector. The company collaborates with a team of biomedical experts and investment professionals to identify and develop emerging life science technologies. TaiAn is dedicated to exploring innovative technology platforms, transforming them into viable business opportunities, and supporting both existing and new entities in the sector. The firm is backed by shareholders that include the Development Fund of the Executive Yuan of Taiwan and several prominent international conglomerates. By leveraging these partnerships and its strong management team, TaiAn Technologies aims to create synergies with Taiwanese corporations, enhancing the value of their investments in biotech and healthcare-related technologies.
Past deals in Taiwan
Aprinoia Therapeutics
Series B in 2018
Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on advancing brain health through innovative diagnostic tools and therapies for neurodegenerative diseases. Founded in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, Aprinoia develops imaging-based diagnostics, including 18F-PM-PBB3, a tau positron-emission tomography (PET) tracer that aids in the diagnosis of tauopathies. The company also manufactures an alpha-synuclein PET imaging tracer. By targeting protein aggregates associated with conditions like Alzheimer's and Parkinson's diseases, Aprinoia aims to enhance precision medicine in neuroscience and improve patient outcomes. The company's commitment to addressing the complexities of neurodegenerative diseases positions it as a leader in the development of first-in-class and best-in-class diagnostic and therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.